Воспалительные заболевания органов малого таза (ВЗОМТ) включают широкий спектр воспалительных процессов, часто ассоциированных с инфекциями, передающимися половым путем (ИППП). В большом числе случаев ВЗОМТ протекают атипично или имеют стертые клинические проявления. Эмпирическая терапия ВЗОМТ обязательна у сексуально активных молодых женщин и в группах риска по ИППП при наличии симптомов воспаления. Парентеральные и пероральные режимы терапии должны перекрывать весь спектр возможных возбудителей, вызывающих ИППП, а также анаэробы и миклофлору, ассоциированную с бактериальным вагинозом.
Ключевые слова: ВЗОМТ, воспаление, ИППП.
________________________________________________
Pelvic inflammatory disease (PID) comprises a spectrum of inflammatory disorders of the upper female genital tract often associated with Sexually Transmitted Diseases (STD). Many women with PID have subtle or mild symptoms which often delay the correct diagnosis and treatment. Empiric treatment for PID should be initiated in sexually active young women and other women at risk of STD in case of symptoms. Parenteral and oral therapy regimes should cover all the range of possible agents of sexually transmitted diseases, and also anaerobes, and microflora associated with bacterial vaginosis.
1. Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 16 (149): 878–84.
2. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: RR-12.
3. Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765–6.
4. RCOG Green Top Guidelines-Management of Pelvic Inflammatory Disease (2003, 2009) (www.rcog.org.uk)
5. Clarke LM, Duerr А, Yeung КН. Recovery of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease. J Infect Dis 1997; 1 (176): 286–8.
6. Cohen CR. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765–6.
7. Гинекология: национальное руководство. Под ред. В.И.Кулакова, И.Б.Манухина, Г.М.Савельевой. М.: ГЭОТАР-Медиа, 2011.
8. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011; 753037.
9. Blake DR. Identification of symptoms that indicate a pelvic examination is necessary to exclude PID in adolescent women. J Pediatr Adolesc Gynecol 2003; 1 (16): 25–30.
10. Korn AP. Risk factors for plasma cell endometritis among women with cervical Chlamydia trachomatis, cervical Neisseria gonorrhoeae, or bacterial vaginosis. Am J Obstet Gynecol 1998; 5 (178): 987–90.
11. Lin HW, Tu YY, Lin SY. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12 (9): 900–4.
12. Hillis SD, Joesoef R, Marchbanks PA et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 163: 1503–9.
13. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. М., 2002.
14. Ness RB, Soper DE, Holley RL. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trail. American J Obstet Gynecol 2002; 186: 929–37.
15. Ross JD. Outpatient antibiotics for pelvic inflammatory disease. BMJ 2001; 322: 251–2.
16. Low N, Welch J, Radcliff K. Developing national outcome standards for the management of gonorrhea and genital Chlamydia in genitourinary medicine clinics. Sex Trans Infect 2004; 80: 223–9.
17. Shih TY, Gaydos CA, Rothman RE. Poor Provider Adherence to the Centers for Disease Control and Prevention Treatment Guidelines in US Emergency Department Visits With a Diagnosis of Pelvic Inflammatory Disease. Sex Trans Dis 2011; 38 (4): 299–305.
18. Jaiyeoba O, Lazenby G, Soper DE. Recommendations and rationale for the treatment of pelvic inflammatory disease. Expert Rev Anti Infect Ther 2011; 9 (1): 61–70.
________________________________________________
1. Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 16 (149): 878–84.
2. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: RR-12.
3. Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765–6.
4. RCOG Green Top Guidelines-Management of Pelvic Inflammatory Disease (2003, 2009) (www.rcog.org.uk)
5. Clarke LM, Duerr А, Yeung КН. Recovery of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease. J Infect Dis 1997; 1 (176): 286–8.
6. Cohen CR. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765–6.
7. Гинекология: национальное руководство. Под ред. В.И.Кулакова, И.Б.Манухина, Г.М.Савельевой. М.: ГЭОТАР-Медиа, 2011.
8. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011; 753037.
9. Blake DR. Identification of symptoms that indicate a pelvic examination is necessary to exclude PID in adolescent women. J Pediatr Adolesc Gynecol 2003; 1 (16): 25–30.
10. Korn AP. Risk factors for plasma cell endometritis among women with cervical Chlamydia trachomatis, cervical Neisseria gonorrhoeae, or bacterial vaginosis. Am J Obstet Gynecol 1998; 5 (178): 987–90.
11. Lin HW, Tu YY, Lin SY. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12 (9): 900–4.
12. Hillis SD, Joesoef R, Marchbanks PA et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 163: 1503–9.
13. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. М., 2002.
14. Ness RB, Soper DE, Holley RL. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trail. American J Obstet Gynecol 2002; 186: 929–37.
15. Ross JD. Outpatient antibiotics for pelvic inflammatory disease. BMJ 2001; 322: 251–2.
16. Low N, Welch J, Radcliff K. Developing national outcome standards for the management of gonorrhea and genital Chlamydia in genitourinary medicine clinics. Sex Trans Infect 2004; 80: 223–9.
17. Shih TY, Gaydos CA, Rothman RE. Poor Provider Adherence to the Centers for Disease Control and Prevention Treatment Guidelines in US Emergency Department Visits With a Diagnosis of Pelvic Inflammatory Disease. Sex Trans Dis 2011; 38 (4): 299–305.
18. Jaiyeoba O, Lazenby G, Soper DE. Recommendations and rationale for the treatment of pelvic inflammatory disease. Expert Rev Anti Infect Ther 2011; 9 (1): 61–70.